MSD’s Lipfendra takes on injectable rivals for cholesterol-lowering market supremacy - Pharmaceutical Technology

Armed with oral administration and a cheaper price tag, Lipfendra is touted as a major advancement for patients. Armed with oral administration and a cheaper price tag, Lipfendra is touted as a major advancement for patients. About 86 million US adults age 20 or older have total cholesterol levels above the recommended level, according to the US Centers for Disease Control and Prevention (CDC). Credit: Mirexon/Shutterstock.com. Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends. With a free Pharmaceutical Technology profile, you can: The…

Source: Pharmaceutical Technology